Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Table 5 First-generation epidermal growth factor receptor tyrosine kinase inhibitor plus chemotherapy for unselected patients with non-small cell lung cancer

Ref.	Treatment	Number of patients	Response rate (%)	Median PFS (mo)	Median OS (mo)
INTACT-1[37]	CDDP + GEM + placebo	363	47	6	10.9
	CDDP + GEM + gefitiniba	365	51	5.8	9.9
	CDDP + GEM + gefitinibb	365	50	5.5	9.9
INTACT-2[38]	CDDP + PTX + placebo	345	29	5.0	9.9
	CDDP + PTX + gefitiniba	345	30	5.3	9.8
	CDDP + PTX + gefitinibb	347	30	4.6	8.7
TRIBUTE[39]	CDDP + PTX + placebo	540	19	4.9	10.5
	CDDP + PTX + erlotinib	539	22	5.1	10.6
TALENT[40]	CDDP + GEM + placebo	586	30	5.6	10.1
	CDDP + GEM + erlotinib	586	32	5.4	9.9

^aDose of gefitinib is 250 mg;

^bDose of gefitinib is 500 mg. EGFR-TKIs: Epidermal growth factor receptor tyrosine kinase inhibitors; NSCLC: Non-small cell lung cancer; PFS: Progression-free survival; OS: Overall survival; CDDP: Cisplatin; GEM: Gemcitabine; PTX: Paclitaxel.